10804 related articles for article (PubMed ID: 12567857)
1. [Studies on antitumor activity of rhEndostatin].
Li HY; Li Y; Liu ZH; Wu HJ; Chen FH; Chen XG
Yao Xue Xue Bao; 2002 Oct; 37(10):763-6. PubMed ID: 12567857
[TBL] [Abstract][Full Text] [Related]
2. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors.
Zhu LP; Xing J; Wang QX; Kou L; Li C; Hu B; Wu ZW; Wang JJ; Xu GX
Eur J Pharmacol; 2009 Sep; 617(1-3):23-7. PubMed ID: 19615993
[TBL] [Abstract][Full Text] [Related]
4. Antitumor interaction of short-course endostatin and ionizing radiation.
Hanna NN; Seetharam S; Mauceri HJ; Beckett MA; Jaskowiak NT; Salloum RM; Hari D; Dhanabal M; Ramchandran R; Kalluri R; Sukhatme VP; Kufe DW; Weichselbaum RR
Cancer J; 2000; 6(5):287-93. PubMed ID: 11079167
[TBL] [Abstract][Full Text] [Related]
5. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
6. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
7. The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism.
Du Z; Hou S
J Urol; 2003 Nov; 170(5):2000-3. PubMed ID: 14532841
[TBL] [Abstract][Full Text] [Related]
8. [Inhibition of tumor growth and metastasis via local administration of recombinant human endostatin adenovirus].
Wu Y; Yang L; Zhao X; Su JM; Hu B; Liu JY; Niu T; Luo Y; Li Q; Wei YQ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Dec; 21(6):557-61. PubMed ID: 15583981
[TBL] [Abstract][Full Text] [Related]
9. [Tea polyphenol inhibit on growth of human nasopharyngeal carcinoma cell and xenograft in nude mice].
Feng GK; Xie BF; Liu ZC; Zhu XF; Ye YL
Ai Zheng; 2002 Apr; 21(4):392-4. PubMed ID: 12452018
[TBL] [Abstract][Full Text] [Related]
10. A quantitative method for measuring the antitumor potency of recombinant human endostatin in vivo.
Xu YF; Zhu LP; Hu B; Rong ZG; Zhu HW; Xu JM; Wu ZW; Wang JJ; Xu GX
Eur J Pharmacol; 2007 Jun; 564(1-3):1-6. PubMed ID: 17346697
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
12. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
13. [Inhibition of mixture of lucid garoderma and lucid garoderma spore on tumor cell in vitro and in vivo].
Chen LJ; Han JX; Yang WY; Lu LJ; Zhang JL; Yang QL; Yuan ST; Ding J
Ai Zheng; 2002 Dec; 21(12):1341-4. PubMed ID: 12520744
[TBL] [Abstract][Full Text] [Related]
14. [Effect of transfection of hEndostatin gene on CNE2 cell xenograft growth in nude mice].
Yue T; Zhang P; Liu P; Deng QL; Ji QM; Li XY; Zhu ZY
Ai Zheng; 2003 Feb; 22(2):148-51. PubMed ID: 12600288
[TBL] [Abstract][Full Text] [Related]
15. Effects of retinoic acid on metastasis and its related proteins in gastric cancer cells in vivo and in vitro.
Wu Q; Chen YQ; Chen ZM; Chen F; Su WJ
Acta Pharmacol Sin; 2002 Sep; 23(9):835-41. PubMed ID: 12230954
[TBL] [Abstract][Full Text] [Related]
16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
17. Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo.
Guo QL; Wu MS; Chen Z
Acta Pharmacol Sin; 2002 Oct; 23(10):946-51. PubMed ID: 12370101
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.
Bandyopadhyay A; López-Casillas F; Malik SN; Montiel JL; Mendoza V; Yang J; Sun LZ
Cancer Res; 2002 Aug; 62(16):4690-5. PubMed ID: 12183427
[TBL] [Abstract][Full Text] [Related]
19. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models.
Ren Z; Wang Y; Jiang W; Dai W; Jiang Y
PLoS One; 2014; 9(9):e107823. PubMed ID: 25229620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
